Bristol Myers Squibb's Growth Portfolio Reaches $7.7 Billion Amidst Investor Caution Over Eliquis Generic Competition
Trendline

Bristol Myers Squibb's Growth Portfolio Reaches $7.7 Billion Amidst Investor Caution Over Eliquis Generic Competition

What's Happening? Bristol Myers Squibb, a prominent pharmaceutical company, reported that its 'growth portfolio' of newer drugs generated nearly $7.7 billion in revenue in a single quarter. This represents a 12% increase compared to the same quarter in 2025. This growth portfolio now accounts for al
AI Generated
This may include content generated using AI tools. Glance teams are making active and commercially reasonable efforts to moderate all AI generated content. Glance moderation processes are improving however our processes are carried out on a best-effort basis and may not be exhaustive in nature. Glance encourage our users to consume the content judiciously and rely on their own research for accuracy of facts. Glance maintains that all AI generated content here is for entertainment purposes only.